NCT01632891View on ClinicalTrials.gov

Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 10, 2014

Primary Completion Date

June 19, 2016

Study Completion Date

June 19, 2016

Conditions
HIV-1 InfectionPf Subclinical Parasitemia
Interventions
DRUG

Lopinavir/ritonavir

Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.

DRUG

Emtricitabine/tenofovir disoproxil fumarate

Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.

DRUG

Efavirenz

Participants received one 600 mg tablet of efavirenz orally once daily.

DRUG

Nevirapine

If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.

DRUG

Trimethoprim/sulfamethoxazole

Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.

Trial Locations (5)

20200

Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho

30100

AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret

40100

Kisumu Crs (31460), Kisumu

Unknown

College of Med. JHU CRS (30301), Blantyre

Joint Clinical Research Centre (JCRC) (12401), Kampala

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

NCT01632891 - Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected | Biotech Hunter | Biotech Hunter